Aptevo Stock Jumps As Acute Myeloid Leukemia Combo Therapy Achieves 100% Clinical Benefit Rate

• Aptevo Therapeutics Inc (NASDAQ: APVO) announced that APVO436, in combination with venetoclax and azacitidine, achieved a 100% clinical benefit rate in venetoclax treatment naïve Acute Myeloid Leukemia (AML) patients.

• The data also showed that APVO436, when given in combination with this standard-of-care regimen, was observed to be generally safe and well tolerated.

• Clinical activity was observed in both monotherapy and combination cohorts.

• CRS was observed in fewer than one-quarter of patients within the safety population and, in most cases, was mild or moderate (grade 1 or 2) and manageable.

• In the Phase 1b trial cohort 2, 16 response-evaluable patients received the combination therapy of venetoclax and azacitidine with APVO436, and 75% experienced clinical benefit.

• 100% of patients in this cohort who had not received venetoclax previously experienced clinical benefit.

• Aptevo plans to initiate a Phase 2 trial in the second half of 2023 to further evaluate APVO436 in combination with venetoclax and azacitidine among frontline and relapsed/refractory AML patients who are venetoclax treatment naïve.

• Price Action: APVO shares are up 65% at $5.66 on the last check Monday.

See more from Benzinga

• Broadcom-Vmware Deal Draws European Regulatory Attention, Rivian Pauses Mercedes-Partnered EV Van Plans For Europe, Credit Suisse Issued Loan On Suspicious Bills: Top Stories Monday, Dec. 12

• Credit Suisse Issued $140M On Suspicious Bills, Raising Questions On Risk Management Efforts

• Trump Received Payment In Gold Bars Wheeled To His Apartment, Among Revelations In Best-Selling Book

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.